COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04713176

Not reported

Not reported

2021-01-19

Terminated

RCT

Randomized

Parallel

Blind label

single-center

Treatment

inclusion criteria: - adults over the age of 19 as of the signed date in written consent - subjects with covid-19 according to rt-pcr test(within 10 days) - subjects who need to be hospitalized and injected remdesivir

- subjects who cannot orally administer the investigational products - subjects who requiring mechanical ventilation or ecmo - acute respiratory distress syndrome(ards), shock, multiple organ dysfunction syndrome - subjects who need administration of immunosuppressants - subjects who are allergic or sensitive to investigational products or its ingredients - crcl < 30 ml/min or egfr < 30 ml/min/1.73m^2 - ast or alt >= 5xuln - subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators

2

Daewoong Pharmaceutical Co. LTD.

19

100

Korea;Republic of

Moderate/severe disease at enrollment

4: Moderate/severe disease at enrollment

240

Proportion of Subjects with Point 7 or Point 8 in the 8 point ordinal scale during 29 days

None

Phase 3

[{"arm_notes": "", "treatment_id": 1099, "treatment_name": "Remdesivir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1681, "treatment_name": "Camostat mesilate+remdesivir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}]